JP2022547716A5 - - Google Patents
Info
- Publication number
- JP2022547716A5 JP2022547716A5 JP2022516375A JP2022516375A JP2022547716A5 JP 2022547716 A5 JP2022547716 A5 JP 2022547716A5 JP 2022516375 A JP2022516375 A JP 2022516375A JP 2022516375 A JP2022516375 A JP 2022516375A JP 2022547716 A5 JP2022547716 A5 JP 2022547716A5
- Authority
- JP
- Japan
- Prior art keywords
- ligase
- targeted
- group
- bind
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901161P | 2019-09-16 | 2019-09-16 | |
| US62/901,161 | 2019-09-16 | ||
| US201962905849P | 2019-09-25 | 2019-09-25 | |
| US62/905,849 | 2019-09-25 | ||
| PCT/IB2020/058535 WO2021053495A1 (en) | 2019-09-16 | 2020-09-14 | Bifunctional degraders and their methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547716A JP2022547716A (ja) | 2022-11-15 |
| JP2022547716A5 true JP2022547716A5 (enExample) | 2023-09-22 |
| JP7785663B2 JP7785663B2 (ja) | 2025-12-15 |
Family
ID=72603497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516375A Active JP7785663B2 (ja) | 2019-09-16 | 2020-09-14 | 二機能性分解誘導薬及びそれらの使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220387602A1 (enExample) |
| EP (1) | EP4031247A1 (enExample) |
| JP (1) | JP7785663B2 (enExample) |
| CN (1) | CN114521196A (enExample) |
| WO (1) | WO2021053495A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| US20240246977A1 (en) * | 2020-12-31 | 2024-07-25 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use |
| EP4304655A1 (en) * | 2021-03-12 | 2024-01-17 | Novartis AG | Fatty acid-bifunctional degrader conjugates and their methods of use |
| CN115232108B (zh) * | 2021-04-23 | 2025-04-18 | 领泰生物医药(绍兴)有限公司 | Sos1降解剂及其制备方法和应用 |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| US20240287076A1 (en) * | 2021-05-05 | 2024-08-29 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
| JP2024522768A (ja) * | 2021-06-16 | 2024-06-21 | バイオセリックス， インコーポレイテッド | Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用 |
| KR20240026939A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| EP4359404A4 (en) * | 2021-06-25 | 2025-06-04 | Celgene Corporation | Cereblon-binding compounds, compositions thereof and methods of treatment therewith |
| JP7555155B2 (ja) * | 2021-08-10 | 2024-09-24 | オップテラ インコーポレイテッド | 新規ｐｌｋ１分解誘導化合物 |
| US20240382600A1 (en) | 2021-09-01 | 2024-11-21 | Novartis Ag | Bifunctional degraders comprising a tead binder |
| CN119823111B (zh) * | 2021-11-18 | 2026-05-05 | 正大天晴药业集团股份有限公司 | 稠合酰亚胺类衍生物 |
| KR20240148322A (ko) * | 2021-12-22 | 2024-10-11 | 아낙시스 파마 피티와이 엘티디 | 이작용성 아릴설폰아미드 화합물 |
| US20250074891A1 (en) * | 2021-12-22 | 2025-03-06 | Anaxis Pharma Pty Ltd. | Bifunctional sulphonamide compounds |
| CN116354933B (zh) * | 2021-12-27 | 2025-06-20 | 青岛普泰科生物医药科技有限公司 | 作为雄激素受体调节剂的杂环化合物及其应用 |
| CA3240051A1 (en) * | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JP7805983B2 (ja) * | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024020221A1 (en) * | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| TW202416953A (zh) * | 2022-08-26 | 2024-05-01 | 日商衛材R&D企管股份有限公司 | 抗體藥物複合物 |
| CN120530094A (zh) * | 2023-01-12 | 2025-08-22 | 田边三菱制药株式会社 | Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法 |
| US20240261416A1 (en) * | 2023-01-31 | 2024-08-08 | Wisconsin Alumni Research Foundation | Synthesis of novel cereblon e3 ligase ligands, compounds formed thereby, and pharmaceutical compositions containing them |
| JP2026519523A (ja) | 2023-05-24 | 2026-06-16 | ビアクティカ セラピューティクス エービー | Ｔｅａｄへの結合剤としての芳香族アミドおよびそのコンジュゲート |
| IL325247A (en) | 2023-06-14 | 2026-02-01 | Astrazeneca Ab | History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| CN117257796B (zh) * | 2023-11-08 | 2025-09-16 | 复旦大学 | 奥巴克拉甲磺酸盐在制备抗bkv药物中的应用 |
| CN120623148A (zh) * | 2024-03-11 | 2025-09-12 | 北京深势科技有限公司 | 一种c-Myc降解剂及其制备方法和用途 |
| WO2025232885A1 (en) * | 2024-05-10 | 2025-11-13 | Beigene (Suzhou) Co., Ltd. | Preparation method of a bruton's tyrosine kinase degrader thereof |
| US20260028345A1 (en) | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026021570A1 (en) * | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026052637A1 (en) * | 2024-09-03 | 2026-03-12 | Monte Rosa Therapeutics Ag | Targeted protein degradation |
| WO2026120044A1 (en) | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
| BRPI0811645A2 (pt) * | 2007-05-30 | 2014-11-11 | Hoffmann La Roche | Inibidores de transcriptase reversa de não-nucleosídeo |
| HRP20110632T1 (hr) * | 2007-09-17 | 2011-10-31 | Abbott Laboratories | N-fenil-diokso-hidropirimidini korisni kao inhibitori virusa hepatitisa c (hcv) |
| AR070027A1 (es) * | 2007-09-17 | 2010-03-10 | Abbott Lab | Agentes anti-infecciosos contra el virus hcv |
| MX2012005155A (es) | 2009-11-03 | 2012-08-31 | Glaxosmithkline Llc | Compuestos de quinazolina. |
| WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US10865205B2 (en) * | 2016-04-22 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use |
| WO2017185031A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| AU2017254702B2 (en) * | 2016-04-22 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| US11285218B2 (en) * | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| CA3042294A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| US20210154184A1 (en) * | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| CN109518406B (zh) | 2017-09-18 | 2021-11-16 | 青岛海尔洗涤电器有限公司 | 一种衣物洗干一体机及其控制方法 |
| US11512080B2 (en) * | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| EP3897631A4 (en) * | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| WO2020160193A2 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021018018A1 (en) * | 2019-07-26 | 2021-02-04 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
| TW202123942A (zh) | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | Ｂｒｄ９雙官能基降解劑及其使用方法 |
-
2020
- 2020-09-14 EP EP20775721.2A patent/EP4031247A1/en active Pending
- 2020-09-14 JP JP2022516375A patent/JP7785663B2/ja active Active
- 2020-09-14 CN CN202080064750.9A patent/CN114521196A/zh active Pending
- 2020-09-14 US US17/642,285 patent/US20220387602A1/en active Pending
- 2020-09-14 WO PCT/IB2020/058535 patent/WO2021053495A1/en not_active Ceased